Elitek and Fasturtec market seen growing on leukemia and oncology demand

The Business Research Company says the global market for Elitek, sold as Fasturtec outside the U.S., is set for notable growth through 2035 as leukemia cases rise, healthcare spending increases and oncology support care expands. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Elitek and Fasturtec are used to prevent or treat high uric acid levels tied to tumor lysis syndrome in cancer patients receiving chemotherapy. - The market’s growth tracks with rising leukemia and cancer cases, which increases demand for supportive oncology drugs in hospitals and specialized cancer centers. - Expanded use of rasburicase-based therapy can help reduce kidney damage risk in high-risk patients.

What happened: - The Business Research Company released its Elitek or Fasturtec Including Segment Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says North America held the largest share of the Elitek or Fasturtec market in 2025. - The report forecasts Asia-Pacific will be the fastest-growing region over the next several years. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company made a free sample and the full report available online: Download the free sample and view the full report.

The details: - Elitek is the U.S. brand name; Fasturtec is the name used outside the United States. - The drug contains rasburicase and is given intravenously. - Rasburicase converts uric acid into allantoin, which the kidneys can eliminate more easily. - The medicine is used for patients with leukemia, lymphoma and other cancers where rapid cell breakdown can drive dangerous uric acid buildup. - The report links prior market expansion to higher chemotherapy use, historic tumor lysis syndrome complication rates, early rasburicase approvals, growth in hospital oncology services and more cancer diagnoses worldwide. - The report says future growth will be driven by the global cancer burden, wider pediatric oncology programs, better early assessment of tumor lysis syndrome risk, more specialized oncology centers and stronger cancer supportive care. - The report flags several trends, including more supportive oncology care, broader use in tumor lysis syndrome management, more hospital-based infusion therapy, expanded pediatric oncology treatment and improved chemotherapy safety protocols. - The report says rising leukemia prevalence is a key driver. - The American Cancer Society reported in 2024 that U.S. leukemia cases rose to 62,770 from 59,610 in 2023. - The report also points to higher healthcare spending as a growth factor. - Statistics Netherlands said healthcare spending in the Netherlands reached about $130.70 billion in 2024, up $9.79 billion, or 8.1%, from 2023.

Between the lines: - The market story is less about a breakthrough drug launch and more about broader cancer-care infrastructure getting stronger. - Growth appears tied to better diagnosis, more aggressive treatment and more supportive care around chemotherapy, which increases the need for tumor lysis syndrome management. - The regional split suggests mature oncology markets remain dominant, while faster growth in Asia-Pacific may reflect widening access to cancer treatment and hospital oncology services.

What's next: - The report says demand should keep rising as cancer incidence grows and oncology programs expand, especially in pediatric care. - Hospitals and specialty centers are likely to remain the main channel for Elitek and Fasturtec use. - The company also highlighted new 2026 report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report lists Saumya Sahay as an expert contact for sales and follow-up inquiries.